Key points are not available for this paper at this time.
Variability in internalization of rituximab was observed and was correlated with impaired B cell depletion. Therefore, slower-internalizing type II mAb should be considered as alternative B cell-depleting agents for the treatment of RA and SLE.
Reddy et al. (Mon,) studied this question.